Human tumor antigens, immunosurveillance, and cancer vaccines

Immunologic Research

Volumn 36, Issue 1-3, 2006, Pages 73-82

  Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cells; Cyclin B1; Dendritic cells; MUC1; Premalignant lesions; T cells

Indexed keywords

CANCER VACCINE; CYCLIN B1; MUCIN 1; TUMOR ANTIGEN; VACCINE;

CANCER GROWTH; CANCER IMMUNIZATION; CELL CYCLE REGULATION; HUMAN; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; LABORATORY TEST; LUNG CANCER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW;

EID: 33947095629     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:36:1:73     Document Type: Review

References (24)

1. Finn OJ, Lotze MT: A decade in the life of tumor immunology. Clin Cancer Res 2001;7:759s-760s.
2. Finn OJ: Tumor-rejection antigens recognized by T lymphocytes. Curr Opin Immunol 1993;5:701-708.
3. Barnd DL, Lan MS, Metzgar RS, Finn OJ: Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989;86:7159-7163.
4. Finn OJ: Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630-641.
5. Graziano DF, Finn OJ: Tumor antigens and tumor antigen discovery. Cancer Treat Res 2004;123:89-111.
6. Kao H, Amoscato AA, Ciborowski P, Finn OJ: A new strategy for tumor antigen discovery based on in vitro priming of naive T cells with dendritic cells. Clin Cancer Res 2001;7:773s-780s.
7. Kao H, Marto JA, Hoffmann TK, et al: Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001;194:1313-1323.
8. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ: MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004;82:249-293.
9. Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ: The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 2000;165:3730-3741.
10. Hiltbold EM, Ciborowski P, Finn OJ: Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res 1998;58:5066-5070.
11. Hiltbold EM, Alter MD, Ciborowski P, Finn OJ: Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells. Cell Immunol 1999;194:143-149.
12. Vlad AM, Muller S, Cudic M, et al: Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 2002;196:1435-1446.
13. Soares MM, Mehta V, Finn OJ: Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 2001;166:6555-6563.
14. Cramer DW, Titus-Ernstoff L, McKolanis JR, et al: Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1125-1131.
15. Carlos CA, Dong HF, Howard OM, Oppenheim JJ, Hanisch FJ, Finn OJ: Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol 2005;175:1628-1635.
16. Suzuki H, Graziano DF, McKolanis J, Finn OJ: T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 2005;11:1521-1526.
17. Yu M, Zhan Q, Finn OJ: Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Mol Immunol 2002;38:981-987.
18. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT: A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996;63:298-304.
19. Ramanathan RK, Lee KM, McKolanis J, et al: Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005;54:254-264.
20. Schmielau J, Finn OJ: Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001;61:4756-4760.
21. Schmielau J, Nalesnik MA, Finn OJ: Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res 2001;7:933s-939s.
22. Finn OJ: Premalignant lesions as targets for cancer vaccines. J Exp Med 2003;198:1623-1626.
23. Finn OJ: Immune response as a biomarker for cancer detection and a lot more. N Engl J Med 2005;353:1288-1290.
24. Egloff AM, Weissfeld J, Land SR, Finn OJ: Evaluation of anticyclin b1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Ann N Y Acad Sci 2005;1062:29-40.